Inhalation therapy for COPD (Chronic Obstructive Pulmonary Disease) is a direct drug delivery method targeting the respiratory tract, primarily used to relieve airway narrowing, reduce inflammatory responses, and improve ventilation function. This therapy delivers medication precisely to the lungs through specialized inhalers, reducing systemic side effects while increasing drug concentration at the target site.
The core of the treatment includes bronchodilators and anti-inflammatory drugs, which can be used alone or in combination depending on the severity of the condition. The main goals are to control symptoms, prevent acute exacerbations, slow disease progression, and enhance patients' quality of life.
1. Short-acting bronchodilators (SABA/SAMA): such as salbutamol, providing rapid relief of acute wheezing, with a duration of 4-6 hours. 2. Long-acting bronchodilators (LABA/LAMA): such as formoterol, with a sustained effect of 12-24 hours, used for long-term control. 3. Inhaled corticosteroids (ICS): reduce airway inflammation, often used in combination with bronchodilators.
Primarily divided into three categories: 1. Metered-dose inhalers (MDI): require coordination with breathing, suitable for rapid medication delivery during acute attacks. 2. Dry powder inhalers (DPI): do not require precise coordination of inhalation and pressing, suitable for long-term use. 3. Nebulizers: convert medication into aerosol form, suitable for patients unable to operate inhalers correctly.
Mainly used for symptom management during stable periods and emergency treatment during acute exacerbations in COPD patients. Symptoms include wheezing, dyspnea, chronic cough, and airflow obstruction shown in pulmonary function tests. Patients with concomitant asthma may also use these medications, but require physician assessment for drug combination.
Contraindications include allergies to drug components, severe arrhythmias, or uncontrolled hypertension. Special populations such as the elderly or those with poor hand coordination should choose appropriate devices, possibly with the aid of medication reservoirs or assistive devices.
Steps for using a metered-dose inhaler: 1. Shake the device before dispensing 2. Exhale deeply, then aim at the mouth 3. Press the spray button while slowly inhaling 4. Hold breath for 10 seconds to promote absorption. Dosage is adjusted based on severity; maintenance therapy typically involves twice daily use, with rescue medication used immediately when symptoms occur.
Dry powder inhalers require rapid deep inhalation, while nebulizers deliver medication continuously for 10-15 minutes via mask or mouthpiece. Physicians will select device type and drug combination based on the patient's ability to operate, lung function, and symptom frequency.
Long-term use can significantly improve diffusing capacity of the lungs for carbon monoxide (DLCO) and the 6-minute walk distance. Clinical studies show that combined use of LABA/ICS reduces the rate of acute exacerbations by 30% and improves daily activity tolerance.
Common side effects include dry mouth, hoarseness, and oropharyngeal candidiasis; rinsing the mouth after medication is recommended. Long-term use of high-dose steroids may lead to osteoporosis or blood sugar fluctuations. A small number of patients may experience palpitations or tremors due to high doses.
Serious Risks: Overuse of short-acting bronchodilators may induce metabolic alkalosis, and allergic reactions such as worsening breathing difficulty require immediate discontinuation and medical attention. Regular monitoring of bone density and blood glucose levels is necessary during long-term therapy.
Contraindications include: 1. Allergies to active ingredients or excipients 2. Uncontrolled coronary artery disease 3. Active pulmonary tuberculosis infection. During use, avoid concurrent use with antihistamines, as they may affect drug absorption.
Operational contraindications: Patients with severe cardiopulmonary failure may be unable to cooperate with inhalation techniques; intravenous administration is recommended. Elderly patients should undergo regular assessment of device usage skills, with caregiver assistance if necessary.
Combination with oral steroids may increase the risk of osteoporosis; calcium and vitamin D supplementation are advised. Caution is needed when used with beta-blockers, as they may exacerbate bronchoconstriction. Antiarrhythmic drugs may affect cardiac metabolic pathways, requiring ECG monitoring.
Herbal preparations (such as ephedrine preparations) may produce additive effects with bronchodilators, leading to blood pressure fluctuations. Patients should inform healthcare providers of inhaled medications before surgery or anesthesia.
Large clinical trials show that regular use of LABA/ICS can delay FEV1 decline by 50% and reduce hospital admissions by 28%. Inhaled anti-muscular atrophy drugs can improve respiratory muscle strength and exercise tolerance.
Long-term follow-up studies confirm that patients using inhalation therapy regularly have a 19% higher survival rate over three years compared to those who do not. The blood concentration of these drugs is 70% lower than oral formulations, significantly reducing hepatic metabolism burden.
Oral bronchodilators or steroids can be used as short-term alternatives but carry higher systemic side effects. Surgical treatments such as bronchial stent placement or lung volume reduction are suitable for severe emphysema unresponsive to medication.
Oxygen therapy can improve peripheral oxygenation but does not directly control inflammation. Alternatives should be carefully evaluated; inhalation therapy remains the first-line option due to its direct action on the affected areas.
After inhalation therapy, it is recommended to rinse the mouth immediately with water to reduce the risk of oral infections and clean the surface of the inhaler. Residual medication from corticosteroid inhalers can cause oral thrush or hoarseness if not cleaned. Store the inhaler in a dry, cool place away from direct sunlight to ensure medication efficacy.
Should I stop medication if I experience throat itching or cough during inhalation therapy?Mild throat discomfort is a common side effect and can be alleviated by using a spacer or increasing mouth rinsing. If symptoms persist for more than three days or are accompanied by difficulty breathing, consult a physician. Adjustments to dosage or adding antihistamines may be necessary, but do not stop medication on your own to avoid affecting disease control.
How can I tell if the medication is properly inhaled into the lungs?Proper inhalation technique is crucial: When using a metered-dose inhaler, press the canister while taking a deep breath, then hold your breath for a few seconds. Observe whether the inhaler sprays evenly with a white mist, or use a demonstration model to confirm correct technique. If symptoms do not improve, revisit your healthcare provider for adjustment.
Can I perform aerobic exercise while undergoing inhalation therapy?Moderate exercise such as walking or jogging is recommended under medical guidance to enhance respiratory muscle endurance. Avoid outdoor activities in extreme cold or heavily polluted air. Using a bronchodilator about an hour before exercise can prevent chest tightness. If wheezing or severe coughing occurs during exercise, stop immediately and consult your doctor.
What is the relationship between long-term effects of inhalation therapy and regular outpatient follow-up?Regular outpatient visits help assess lung function improvement and adjust medication types and dosages based on oxygen saturation and dyspnea indices. Patients who use inhalation therapy regularly over the long term experience a 30-50% reduction in acute exacerbations, but comprehensive management including smoking cessation and vaccination is necessary for optimal outcomes.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
